

Table S1. Summarized patient and tumor characteristics of the entire cohort

Characteristic	Value
Age (yr)	41 (25–52)
≤ 20	884 (19.4)
> 20 and ≤ 47	2,081 (45.7)
> 47	1,589 (34.9)
Sex	
Male	2,537 (55.7)
Female	2,017 (44.3)
Subtype	
Lymphoid leukemia (C91)	1,512 (33.2)
Myeloid leukemia (C92)	2,510 (55.1)
Others (C93–C95)	342 (7.5)
Insurance	
Medicaid	276 (6.1)
Medicare	4,278 (93.9)
Hospital location (provinces)	
Seoul	3,093 (67.9)
Gyeonggi	419 (9.2)
Gyeongsang	646 (14.2)
Jeolla	283 (6.2)
Chungcheong/Gangwon	113 (2.5)
Hospital volume	
≤ 200 cases	1,498 (32.9)
> 200 cases	3,056 (67.1)
CCI	2 (2–2)
0–2	3,511 (77.1)
3	836 (18.4)
≥ 4	207 (4.5)
Year of transplantation	
2009–2012	2,024 (44.4)
2013–2016	2,530 (55.6)
Chemotherapy	
Bu/Flu or Bu/Flu containing CTx	2,324 (51.0)
Bu/Cy or BuCy containing CTx	869 (19.1)
Cy or Cy containing CTx	685 (15.0)
Cy/Flu or Cy/Flu containing CTx	72 (1.6)
AraC or AraC containing CTx	297 (6.5)
Flu or Flu containing Ctx	267 (5.9)
Other	40 (0.9)
ATG	
Not administered	2,149 (47.2)
Administered	2,405 (52.8)
TBI	
Not done	3,145 (69.1)
Done	1,409 (30.9)

Values are presented as median (interquartile range) or number (%).

TBI, total body irradiation; CCI, Charlson Comorbidity Index; Bu, busulfan; Flu, fludarabine; Cy, cyclophosphamide; CTx, chemotherapy, AraC, cytarabine; ATG, anti-thymocyte globulin.